In this episode of OncoDaily, Dr. Petros Grivas joins host Chandler Park to discuss the groundbreaking NIAGARA study presented at ESMO 2024. This global, multicenter trial investigated the perioperative use of dr combined with chemotherapy for localized muscle-invasive bladder cancer, enrolling over 1,000 patients. Dr. Grivas highlights the study’s promising results in event-free and overall survival, while also addressing critical questions about the necessity of both neoadjuvant and adjuvant treatments. They further explore the role of biomarkers and ctDNA in patient selection and discuss future directions for refining treatment strategies for bladder cancer.
@EsmoOrgMedicalOncology

#DrPetrosGrivas #OncoDaily #ChandlerPark #NIAGARAStudy #ESMO2024 #BladderCancer #Durvalumab #Chemotherapy #MuscleInvasiveBladderCancer #ClinicalTrials #Cancer #CancerResearch #EventFreeSurvival #OverallSurvival #NeoadjuvantTreatment #AdjuvantTreatment #Biomarkers #ctDNA #PatientSelection #TreatmentStrategies #GlobalHealth #MulticenterTrial #Oncology #CancerTreatment #HealthcareInnovation #BladderCancerAwareness

01:10 Highlights of Niagara Trial
09:00 Neoadjuvant Insights
02:05 Balancing Treatment Strategies
15:00 Conclusion

SUBSCRIBE to get the latest #oncodaily [ Ссылка ]

Visit the OncoDaily Website : [ Ссылка ]
Like OncoDaily on LinkedIn: [ Ссылка ]
Like OncoDaily on X (Twitter): [ Ссылка ]
Follow OncoDaily on Instagram: [ Ссылка ]
Follow OncoDaily on TikTok: [ Ссылка ]
Like OncoDaily on Facebook: [ Ссылка ]

SUBSCRIBE to OncoDaily Newsletter: [ Ссылка ]

About OncoDaily
OncoDaily is a world-leading oncology media platform, which is based in the United States and features the cancer related latest news, insights, and patient stories from around the globe. The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”

свернуть